Breaking News Instant updates and real-time market news.

ALDX

Aldeyra

$2.64 /

+0.14 (+5.60%)

08:10
05/18/22
05/18
08:10
05/18/22
08:10

Aldeyra reports post-hoc analysis from TRANQUILITY trial

Aldeyra reported that a post-hoc analysis using computer automated grading of digital photography from the completed Phase 3 TRANQUILITY dry eye chamber trial demonstrated statistical significance in favor of reproxalap over vehicle for the primary endpoint of reduction of ocular redness. As previously announced, the Phase 3 TRANQUILITY trial failed to meet the primary endpoint of ocular redness as assessed by independent central reviewers. When applied to Aldeyra's Phase 2 dry eye chamber trial, which was completed in late 2021, the computer automated grading assessment confirmed the previously announced achievement of the primary endpoint of ocular redness, which, similar to the Phase 3 TRANQUILITY trial, was originally assessed by independent central reviewers. Aldeyra intends to discuss the results of the post-hoc analyses, as well as the algorithm used for the computer automated assessment of ocular redness,1 with the FDA prior to NDA submission. The computer automated grading of redness in the completed Phase 3 TRANQUILITY and Phase 2 clinical trials of reproxalap is based on digital images captured by portable cameras fitted with eye cups to standardize distance, lighting, focus, hue, and contrast. The assessment consisted of automated selection of temporal conjunctiva from images of subjects focusing on nasal targets in the eye cup. Redness intensity was averaged across all pixels in the selected region, and combined with vessel geometry to generate a theoretical maximum score of 255. The average baseline score from the post-hoc analyses of the Phase 3 TRANQUILITY and Phase 2 clinical trials was approximately 18. Per draft FDA guidance, to be considered for regulatory approval in the United States, a product candidate for the treatment of dry eye disease must, with certain exceptions, demonstrate efficacy in an objective sign in at least two clinical trials and efficacy in a subjective symptom in at least two clinical trials. Statistical significance versus vehicle is generally considered sufficient for demonstration of efficacy. For satisfaction of symptom efficacy requirements, Aldeyra intends to submit two previously completed adequate and well-controlled 12-week symptom trials that pre-specified patient-reported ocular dryness score as a primary endpoint, the Phase 3 RENEW-Part 1 and Formulation Phase 2 clinical trials. Pending discussion with the FDA, for satisfaction of the sign efficacy requirements, Aldeyra intends to submit the ocular redness results from the Phase 3 TRANQUILITY and Phase 2 dry eye chamber trials. If the primary endpoint of Schirmer test is achieved in the Phase 3 TRANQUILITY-2 trial, and pending discussion with the FDA, Aldeyra intends to submit Schirmer test results from both TRANQUILITY trials as evidence for achievement of an additional objective sign of dry eye disease. Top-line results from TRANQUILITY-2 are expected in the second quarter of 2022. Pending discussion with the FDA and enrollment of the ongoing 12-month safety trial in dry eye disease patients, NDA submission for dry eye disease is expected to occur mid-2022.

  • 07

    Jun

OTHER BREAKING NEWS FROM THE FLY

Recommendations
Bill.com price target lowered to $177 from $265 at Deutsche Bank » 06:10
07/07/22
07/07
06:10
07/07/22
06:10
BILL

Bill.com

$123.31 /

-3.1 (-2.45%)

Deutsche Bank analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BILL Bill.com
$123.31 /

-3.1 (-2.45%)

BILL Bill.com
$123.31 /

-3.1 (-2.45%)

06/17/22 Oppenheimer
Bill.com price target lowered to $150 from $190 at Oppenheimer
06/16/22 Piper Sandler
Bill.com price target raised to $212 from $205 at Piper Sandler
05/31/22 KeyBanc
Bill.com price target lowered to $175 from $225 at KeyBanc
05/24/22 Piper Sandler
Bill.com price target lowered to $205 from $300 at Piper Sandler
BILL Bill.com
$123.31 /

-3.1 (-2.45%)

  • 22
    Sep
BILL Bill.com
$123.31 /

-3.1 (-2.45%)

BILL Bill.com
$123.31 /

-3.1 (-2.45%)

Hot Stocks
Terran Orbital announces deployment of CAPSTONE spacecraft » 06:09
07/07/22
07/07
06:09
07/07/22
06:09
LLAP

Terran Orbital

$4.57 /

+0.22 (+5.06%)

Terran Orbital…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LLAP Terran Orbital
$4.57 /

+0.22 (+5.06%)

LLAP Terran Orbital
$4.57 /

+0.22 (+5.06%)

06/15/22 BofA
Terran Orbital initiated with Buy on government demand at BofA
06/15/22 BofA
Terran Orbital initiated with a Buy at BofA
05/16/22 Canaccord
Terran Orbital price target lowered to $18 from $22 at Canaccord
04/20/22 Jefferies
Terran Orbital initiated with a Buy at Jefferies
LLAP Terran Orbital
$4.57 /

+0.22 (+5.06%)

LLAP Terran Orbital
$4.57 /

+0.22 (+5.06%)

Initiation
Duolingo initiated with a Buy at Needham » 06:09
07/07/22
07/07
06:09
07/07/22
06:09
DUOL

Duolingo

$96.84 /

-2.47 (-2.49%)

Needham analyst Ryan…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
DUOL Duolingo
$96.84 /

-2.47 (-2.49%)

DUOL Duolingo
$96.84 /

-2.47 (-2.49%)

06/24/22 Piper Sandler
Duolingo price target raised to $119 from $95 at Piper Sandler
06/10/22 Goldman Sachs
Duolingo price target lowered to $84 from $106 at Goldman Sachs
05/13/22 Evercore ISI
Duolingo removed from 'Tactical Outperform' list at Evercore
05/13/22 BofA
Duolingo price target lowered to $135 from $165 at BofA
DUOL Duolingo
$96.84 /

-2.47 (-2.49%)

  • 28
    Jul
DUOL Duolingo
$96.84 /

-2.47 (-2.49%)

Recommendations
Conifer Holdings price target lowered to $2 from $2.50 at Piper Sandler » 06:08
07/07/22
07/07
06:08
07/07/22
06:08
CNFR

Conifer Holdings

$1.76 /

+ (+0.00%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CNFR Conifer Holdings
$1.76 /

+ (+0.00%)

Hot Stocks
Deluxe appoints Jean Herrick as CHRO, Cameron Potts as CCO » 06:08
07/07/22
07/07
06:08
07/07/22
06:08
DLX

Deluxe

$20.79 /

-0.76 (-3.53%)

Deluxe recently announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
DLX Deluxe
$20.79 /

-0.76 (-3.53%)

DLX Deluxe
$20.79 /

-0.76 (-3.53%)

04/27/22 Cowen
Deluxe price target lowered to $42 from $50 at Cowen
02/04/22 Cowen
Deluxe price target lowered to $50 from $55 at Cowen
09/01/21 Cowen
Cowen starts 'payments and business tech leader' Deluxe at Outperform
09/01/21 Cowen
Deluxe initiated with an Outperform at Cowen
DLX Deluxe
$20.79 /

-0.76 (-3.53%)

Hot Stocks
Cedar Fair reports record revenues through July 4th weekend » 06:05
07/07/22
07/07
06:05
07/07/22
06:05
FUN

Cedar Fair

$46.62 /

-0.53 (-1.12%)

Cedar Fair Entertainment…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FUN Cedar Fair
$46.62 /

-0.53 (-1.12%)

FUN Cedar Fair
$46.62 /

-0.53 (-1.12%)

06/28/22 Deutsche Bank
Cedar Fair dividend closer after sale-leaseback deal, says Deutsche Bank
06/21/22 B. Riley
Cedar Fair price target lowered to $68 from $80 at B. Riley
05/05/22 B. Riley
Cedar Fair price target raised to $80 from $76 at B. Riley
05/05/22 Deutsche Bank
Cedar Fair price target raised to $75 from $70 at Deutsche Bank
FUN Cedar Fair
$46.62 /

-0.53 (-1.12%)

FUN Cedar Fair
$46.62 /

-0.53 (-1.12%)

FUN Cedar Fair
$46.62 /

-0.53 (-1.12%)

Upgrade
PPL Corp. upgraded to Outperform from In Line at Evercore ISI » 06:05
07/07/22
07/07
06:05
07/07/22
06:05
PPL

PPL Corp.

/

+

Evercore ISI analyst Greg…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PPL PPL Corp.
/

+

PPL PPL Corp.
/

+

06/07/22 Wells Fargo
PPL Corp. price target raised to $34 from $33 at Wells Fargo
05/30/22 Goldman Sachs
PPL Corp. reinstated with a Buy at Goldman Sachs
04/25/22 Credit Suisse
PPL Corp. initiated with an Outperform at Credit Suisse
04/04/22 Argus
PPL Corp. downgraded to Hold from Buy at Argus
PPL PPL Corp.
/

+

Upgrade
Whitestone REIT upgraded to Outperform from Market Perform at JMP Securities » 06:05
07/07/22
07/07
06:05
07/07/22
06:05
WSR

Whitestone REIT

$10.21 /

-0.385 (-3.64%)

JMP Securities analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
WSR Whitestone REIT
$10.21 /

-0.385 (-3.64%)

WSR Whitestone REIT
$10.21 /

-0.385 (-3.64%)

06/15/22 EF Hutton
Whitestone REIT initiated with a Buy at EF Hutton
04/06/22 Colliers
Whitestone REIT initiated with a Buy at Colliers
03/03/22 B. Riley
Whitestone REIT price target raised to $13 from $10.50 at B. Riley
Hot Stocks
Immuron granted European patent for treatment of Clostridioides difficile » 06:05
07/07/22
07/07
06:05
07/07/22
06:05
IMRN

Immuron

$2.19 /

-0.1 (-4.37%)

Immuron has received…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
IMRN Immuron
$2.19 /

-0.1 (-4.37%)

Downgrade
Sealed Air downgraded to Neutral from Buy at BofA » 06:04
07/07/22
07/07
06:04
07/07/22
06:04
SEE

Sealed Air

$58.43 /

+0.74 (+1.28%)

BofA analyst George…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SEE Sealed Air
$58.43 /

+0.74 (+1.28%)

SEE Sealed Air
$58.43 /

+0.74 (+1.28%)

06/01/22 JPMorgan
Sealed Air downgraded to Underweight from Neutral at JPMorgan
04/08/22 Citi
Sealed Air price target lowered to $80 from $81 at Citi
02/25/22 JPMorgan
Sealed Air downgraded to Neutral from Overweight at JPMorgan
02/18/22 Mizuho
Sealed Air price target raised to $72 from $68 at Mizuho
SEE Sealed Air
$58.43 /

+0.74 (+1.28%)

SEE Sealed Air
$58.43 /

+0.74 (+1.28%)

Downgrade
Kohl's downgraded to Neutral from Buy at BofA » 06:04
07/07/22
07/07
06:04
07/07/22
06:04
KSS

Kohl's

$27.38 /

-1.97 (-6.71%)

BofA analyst Lorraine…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
KSS Kohl's
$27.38 /

-1.97 (-6.71%)

KSS Kohl's
$27.38 /

-1.97 (-6.71%)

07/05/22 Guggenheim
Kohl's price target lowered to $44 from $68 at Guggenheim
07/05/22 Baird
Kohl's price target lowered to $42 from $53 at Baird
07/05/22 Deutsche Bank
Kohl's valuation attractive after 20% selloff, says Deutsche Bank
07/05/22 UBS
Kohl's end of review process a 'significant' negative, says UBS
KSS Kohl's
$27.38 /

-1.97 (-6.71%)

KSS Kohl's
$27.38 /

-1.97 (-6.71%)

KSS Kohl's
$27.38 /

-1.97 (-6.71%)

KSS Kohl's
$27.38 /

-1.97 (-6.71%)

Initiation
Global Medical REIT initiated with a Market Perform at JMP Securities » 06:03
07/07/22
07/07
06:03
07/07/22
06:03
GMRE

Global Medical REIT

$11.20 /

+0.01 (+0.09%)

JMP Securities analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GMRE Global Medical REIT
$11.20 /

+0.01 (+0.09%)

06/06/22 Baird
Global Medical REIT weakness a buying opportunity, says Baird
05/10/22 B. Riley
Global Medical REIT price target lowered to $16 from $18 at B. Riley
03/02/22 B. Riley
Global Medical REIT price target lowered to $18 from $20 at B. Riley
01/13/22 KeyBanc
Global Medical REIT downgraded to Sector Weight from Overweight at KeyBanc
GMRE Global Medical REIT
$11.20 /

+0.01 (+0.09%)

Hot Stocks
High Tide to acquire six stores from Choom Holdings for C$5.1M » 06:03
07/07/22
07/07
06:03
07/07/22
06:03
HITI

High Tide

$2.06 /

-0.05 (-2.37%)

, CHOOF

Choom Holdings

/

+

High Tide (HITI)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
HITI High Tide
$2.06 /

-0.05 (-2.37%)

HITI High Tide
$2.06 /

-0.05 (-2.37%)

01/31/22 Desjardins
High Tide price target lowered to C$11.50 from C$13.50 at Desjardins
11/22/21 Cantor Fitzgerald
High Tide initiated with a Neutral at Cantor Fitzgerald
10/22/21 Desjardins
High Tide price target lowered to C$13.50 from C$15 at Desjardins
10/07/21 Roth Capital
Roth Capital views High Tide acquisition of Blessed CBD 'favorably'
CHOOF Choom Holdings
/

+

HITI High Tide
$2.06 /

-0.05 (-2.37%)

HITI High Tide
$2.06 /

-0.05 (-2.37%)

Downgrade
Rio Tinto downgraded to Sell from Hold at Berenberg » 05:59
07/07/22
07/07
05:59
07/07/22
05:59
RIO

Rio Tinto

$57.28 /

+ (+0.00%)

Berenberg analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RIO Rio Tinto
$57.28 /

+ (+0.00%)

RIO Rio Tinto
$57.28 /

+ (+0.00%)

07/06/22 Credit Suisse
Rio Tinto assumed with an Outperform at Credit Suisse
07/05/22 JPMorgan
Rio Tinto price target lowered to 5,420 GBp from 5,730 GBp at JPMorgan
06/29/22 Deutsche Bank
Rio Tinto price target lowered to 5,800 GBp from 6,000 GBp at Deutsche Bank
06/22/22 Morgan Stanley
Rio Tinto downgraded to Equal Weight at Morgan Stanley
RIO Rio Tinto
$57.28 /

+ (+0.00%)

RIO Rio Tinto
$57.28 /

+ (+0.00%)

RIO Rio Tinto
$57.28 /

+ (+0.00%)

General news
Boris Johnson to step down as British prime minister, WSJ reports » 05:57
07/07/22
07/07
05:57
07/07/22
05:57
SPX

S&P 500

/

+

, SPY

SPDR S&P 500 ETF Trust

$383.31 /

+1.34 (+0.35%)

Boris Johnson will step…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SPX S&P 500
/

+

SPY SPDR S&P 500 ETF Trust
$383.31 /

+1.34 (+0.35%)

SPX S&P 500
/

+

07/01/22 JPMorgan
JPMorgan forecast 'perilously close' to recession after GDP cuts
06/27/22 Citi
Citi cuts S&P 500 year-end target, sees positive second half setup
05/19/22 Goldman Sachs
Goldman Sachs sees 35% chance of U.S. recession in next two years
03/07/22 Citi
Citi lowers year-end 2022 S&P 500 target on geopolitical risk
SPY SPDR S&P 500 ETF Trust
$383.31 /

+1.34 (+0.35%)

07/01/22 JPMorgan
JPMorgan forecast 'perilously close' to recession after GDP cuts
06/27/22 Citi
Citi cuts S&P 500 year-end target, sees positive second half setup
05/19/22 Goldman Sachs
Goldman Sachs sees 35% chance of U.S. recession in next two years
03/07/22 Citi
Citi lowers year-end 2022 S&P 500 target on geopolitical risk
SPX S&P 500
/

+

SPY SPDR S&P 500 ETF Trust
$383.31 /

+1.34 (+0.35%)

SPX S&P 500
/

+

SPY SPDR S&P 500 ETF Trust
$383.31 /

+1.34 (+0.35%)

SPX S&P 500
/

+

SPY SPDR S&P 500 ETF Trust
$383.31 /

+1.34 (+0.35%)

SPX S&P 500
/

+

SPX S&P 500
/

+

SPY SPDR S&P 500 ETF Trust
$383.31 /

+1.34 (+0.35%)

Downgrade
Segro downgraded to Underperform from Neutral at Exane BNP Paribas » 05:57
07/07/22
07/07
05:57
07/07/22
05:57
SEGXF

Segro

$11.98 /

+ (+0.00%)

Exane BNP Paribas…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SEGXF Segro
$11.98 /

+ (+0.00%)

07/05/22 Barclays
Segro price target lowered to 1,300 GBp from 1,545 GBp at Barclays
05/03/22 Kepler Cheuvreux
Segro downgraded to Reduce from Hold at Kepler Cheuvreux
03/31/22 Goldman Sachs
Segro downgraded to Buy from Conviction Buy at Goldman Sachs
03/23/22 JPMorgan
Segro price target raised to 1,585 GBp from 1,450 GBp at JPMorgan
Hot Stocks
Shell revises up value of oil and gas assets ahead of July 28 results » 05:56
07/07/22
07/07
05:56
07/07/22
05:56
SHEL

Shell

$48.00 /

-0.585 (-1.20%)

Shell said in a trading…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SHEL Shell
$48.00 /

-0.585 (-1.20%)

SHEL Shell
$48.00 /

-0.585 (-1.20%)

07/06/22 Deutsche Bank
Shell price target raised to 2,779 GBp from 2,551 GBp at Deutsche Bank
06/09/22 Credit Suisse
Shell initiated with an Outperform at Credit Suisse
05/11/22 Morgan Stanley
Shell price target raised to 2,860 GBp from 2,570 GBp at Morgan Stanley
05/06/22 UBS
Shell price target raised to 2,550 GBp from 2,450 GBp at UBS
SHEL Shell
$48.00 /

-0.585 (-1.20%)

SHEL Shell
$48.00 /

-0.585 (-1.20%)

SHEL Shell
$48.00 /

-0.585 (-1.20%)

SHEL Shell
$48.00 /

-0.585 (-1.20%)

Downgrade
Kellogg downgraded to Neutral from Buy at UBS » 05:54
07/07/22
07/07
05:54
07/07/22
05:54
K

Kellogg

$72.73 /

+0.485 (+0.67%)

UBS analyst Cody Ross…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
K Kellogg
$72.73 /

+0.485 (+0.67%)

K Kellogg
$72.73 /

+0.485 (+0.67%)

06/22/22 JPMorgan
Kellogg breakup likely doesn't alter share valuation, says JPMorgan
06/22/22 Deutsche Bank
Kellogg price target lowered to $72 from $74 at Deutsche Bank
06/22/22 Citi
Kellogg price target raised to $87 from $83 at Citi
06/21/22 Stifel
Stifel views Kellogg breakup announcement as positive for stock
K Kellogg
$72.73 /

+0.485 (+0.67%)

K Kellogg
$72.73 /

+0.485 (+0.67%)

K Kellogg
$72.73 /

+0.485 (+0.67%)

K Kellogg
$72.73 /

+0.485 (+0.67%)

Upgrade
Lamar Advertising upgraded to Buy from Neutral at Citi » 05:51
07/07/22
07/07
05:51
07/07/22
05:51
LAMR

Lamar Advertising

$88.37 /

+0.105 (+0.12%)

Citi analyst Jason…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LAMR Lamar Advertising
$88.37 /

+0.105 (+0.12%)

06/10/22 Morgan Stanley
Lamar downgraded to Equal Weight on recession risk at Morgan Stanley
06/10/22 Morgan Stanley
Lamar Advertising downgraded to Equal Weight from Overweight at Morgan Stanley
03/29/22 Wolfe Research
Lamar Advertising initiated with a Peer Perform at Wolfe Research
07/19/21 Morgan Stanley
Morgan Stanley equity strategist upgrades Consumer Staples, downgrades Materials
LAMR Lamar Advertising
$88.37 /

+0.105 (+0.12%)

LAMR Lamar Advertising
$88.37 /

+0.105 (+0.12%)

Upgrade
Endeavor Group upgraded to Buy from Neutral at Citi » 05:51
07/07/22
07/07
05:51
07/07/22
05:51
EDR

Endeavor Group

$21.16 /

-0.39 (-1.81%)

Citi analyst Jason…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EDR Endeavor Group
$21.16 /

-0.39 (-1.81%)

EDR Endeavor Group
$21.16 /

-0.39 (-1.81%)

07/01/22 Barclays
Endeavor Group price target raised to $28 from $27 at Barclays
06/23/22 Credit Suisse
Endeavor Group assumed with an Outperform at Credit Suisse
06/15/22 Morgan Stanley
Morgan Stanley upgrades Liberty Formula One, names Endeavor top pick
05/17/22 Goldman Sachs
Endeavor Group upgraded to Buy from Neutral at Goldman Sachs
EDR Endeavor Group
$21.16 /

-0.39 (-1.81%)

EDR Endeavor Group
$21.16 /

-0.39 (-1.81%)

EDR Endeavor Group
$21.16 /

-0.39 (-1.81%)

Periodicals
Merck in advanced talks to buy Seagen for $40B+, WSJ reports » 05:50
07/07/22
07/07
05:50
07/07/22
05:50
MRK

Merck

$93.16 /

+0.52 (+0.56%)

, SGEN

Seagen

$175.15 /

-1.78 (-1.01%)

Merck (MRK) is in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MRK Merck
$93.16 /

+0.52 (+0.56%)

SGEN Seagen
$175.15 /

-1.78 (-1.01%)

MRK Merck
$93.16 /

+0.52 (+0.56%)

05:10 Today Daiwa
Merck upgraded to Outperform from Neutral at Daiwa (yesterday)
07/06/22 Daiwa
Merck upgraded to Buy from Neutral at Daiwa
06/29/22 Raymond James
Seagen initiated with an Outperform at Raymond James
06/28/22 Piper Sandler
Sutro Biopharma price target raised to $16 from $14 at Piper Sandler
SGEN Seagen
$175.15 /

-1.78 (-1.01%)

06/29/22 Raymond James
Seagen initiated with an Outperform at Raymond James
06/28/22 Piper Sandler
Sutro Biopharma price target raised to $16 from $14 at Piper Sandler
06/27/22 Cowen
Merck price target raised to $102 from $95 at Cowen
06/24/22 Mizuho
Merck deal would add 'novel and validated technology,' says Mizuho
MRK Merck
$93.16 /

+0.52 (+0.56%)

SGEN Seagen
$175.15 /

-1.78 (-1.01%)

MRK Merck
$93.16 /

+0.52 (+0.56%)

SGEN Seagen
$175.15 /

-1.78 (-1.01%)

MRK Merck
$93.16 /

+0.52 (+0.56%)

SGEN Seagen
$175.15 /

-1.78 (-1.01%)

MRK Merck
$93.16 /

+0.52 (+0.56%)

Periodicals
Microsoft cloud exec leaving after allegations of verbal abuse, Bloomberg says » 05:48
07/07/22
07/07
05:48
07/07/22
05:48
MSFT

Microsoft

$266.22 /

+3.35 (+1.27%)

Tom Keane, a Microsoft VP…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MSFT Microsoft
$266.22 /

+3.35 (+1.27%)

MSFT Microsoft
$266.22 /

+3.35 (+1.27%)

07/06/22 Needham
RingCentral downgraded to Hold from Buy at Needham
06/29/22 Redburn
Microsoft initiated with a Buy at Redburn
06/27/22 William Blair
Okta not seeing backlash from security breach, says William Blair
06/24/22 Citi
Citi names top software picks with sector de-rating 'mostly done'
MSFT Microsoft
$266.22 /

+3.35 (+1.27%)

MSFT Microsoft
$266.22 /

+3.35 (+1.27%)

MSFT Microsoft
$266.22 /

+3.35 (+1.27%)

MSFT Microsoft
$266.22 /

+3.35 (+1.27%)

Upgrade
1Life Healthcare upgraded to Buy from Neutral at BTIG » 05:47
07/07/22
07/07
05:47
07/07/22
05:47
ONEM

1Life Healthcare

$10.29 /

-0.07 (-0.68%)

, CVS

CVS Health

$93.20 /

+0.67 (+0.72%)

, UNH

UnitedHealth

$515.28 /

+10.54 (+2.09%)

, ELV

Elevance Health

$484.65 /

+8.295 (+1.74%)

BTIG analyst David Larsen…

BTIG analyst David Larsen upgraded 1Life Healthcare (ONEM) to Buy from Neutral with a $15 price target. Over the past two years, the stock has traded down from $60 to $10, making the multiple "far more reasonable now than it has been in the past," Larsen tells investors in a research note. The analyst also believes that the odds of 1Life being acquired are "fairly high." While the stock rallied 25% on July 5 following a Bloomberg article discussing a possible takeout, 1Life has further valuation upside potential driven by improving Medicare margins, steady membership and revenue growth, cross-sales between Medicare and Commercial, an abatement of COVID, and "well-managed" expectations, contends Larsen. He believes potential acquirers of the business include CVS Health (CVS), a large health plan such as UnitedHealth Group (UNH) or Elevance Health (ELV), or possibly a large publicly traded hospital system. A strategic takeout "seems a very real possibility," writes Larsen.

ShowHide Related Items >><<
ONEM 1Life Healthcare
$10.29 /

-0.07 (-0.68%)

CVS CVS Health
$93.20 /

+0.67 (+0.72%)

UNH UnitedHealth
$515.28 /

+10.54 (+2.09%)

ELV Elevance Health
$484.65 /

+8.295 (+1.74%)

ONEM 1Life Healthcare
$10.29 /

-0.07 (-0.68%)

07/06/22 Deutsche Bank
1Life would not check 'earnings box' for CVS, says Deutsche Bank
07/06/22 Citi
Citi not seeing 'wide buyer universe' for 1Life outside of CVS
07/05/22 Stifel
Stifel says 'logical to assume' Walgreens could look at 1Life Healthcare
06/16/22 Deutsche Bank
1Life Healthcare market cap now below last private raise, says Deutsche Bank
CVS CVS Health
$93.20 /

+0.67 (+0.72%)

07/06/22 Deutsche Bank
1Life would not check 'earnings box' for CVS, says Deutsche Bank
07/06/22 Citi
Citi not seeing 'wide buyer universe' for 1Life outside of CVS
07/05/22 Stifel
Stifel says 'logical to assume' Walgreens could look at 1Life Healthcare
06/16/22 Loop Capital
Loop Capital starts CVS Health at Buy citing position to capitalize on Medicare
UNH UnitedHealth
$515.28 /

+10.54 (+2.09%)

07/05/22 Stifel
Stifel says 'logical to assume' Walgreens could look at 1Life Healthcare
06/16/22 Loop Capital
Loop starts UnitedHealth at Buy, sees company having 'major' advantages
06/16/22 Loop Capital
UnitedHealth initiated with a Buy at Loop Capital
06/01/22 Citi
Change Healthcare price target raised to $27.75 from $25.75 at Citi
ELV Elevance Health
$484.65 /

+8.295 (+1.74%)

ONEM 1Life Healthcare
$10.29 /

-0.07 (-0.68%)

CVS CVS Health
$93.20 /

+0.67 (+0.72%)

UNH UnitedHealth
$515.28 /

+10.54 (+2.09%)

ONEM 1Life Healthcare
$10.29 /

-0.07 (-0.68%)

CVS CVS Health
$93.20 /

+0.67 (+0.72%)

UNH UnitedHealth
$515.28 /

+10.54 (+2.09%)

ONEM 1Life Healthcare
$10.29 /

-0.07 (-0.68%)

CVS CVS Health
$93.20 /

+0.67 (+0.72%)

UNH UnitedHealth
$515.28 /

+10.54 (+2.09%)

ONEM 1Life Healthcare
$10.29 /

-0.07 (-0.68%)

CVS CVS Health
$93.20 /

+0.67 (+0.72%)

UNH UnitedHealth
$515.28 /

+10.54 (+2.09%)

Periodicals
Shell still investing in Gulf amid climate, political debate, WSJ reports » 05:46
07/07/22
07/07
05:46
07/07/22
05:46
SHEL

Shell

$48.00 /

-0.585 (-1.20%)

, EQNR

Equinor

$32.88 /

-0.64 (-1.91%)

Shell (SHEL) is investing…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SHEL Shell
$48.00 /

-0.585 (-1.20%)

EQNR Equinor
$32.88 /

-0.64 (-1.91%)

SHEL Shell
$48.00 /

-0.585 (-1.20%)

07/06/22 Deutsche Bank
Shell price target raised to 2,779 GBp from 2,551 GBp at Deutsche Bank
06/09/22 Credit Suisse
Shell initiated with an Outperform at Credit Suisse
05/11/22 Morgan Stanley
Shell price target raised to 2,860 GBp from 2,570 GBp at Morgan Stanley
05/06/22 UBS
Shell price target raised to 2,550 GBp from 2,450 GBp at UBS
EQNR Equinor
$32.88 /

-0.64 (-1.91%)

07/06/22 Deutsche Bank
Equinor price target raised to NOK 354 from NOK 314 at Deutsche Bank
06/17/22 JPMorgan
Equinor upgraded to Neutral from Underweight at JPMorgan
06/09/22 Credit Suisse
Equinor initiated with a Neutral at Credit Suisse
05/20/22 Societe Generale
Equinor downgraded to Hold from Buy at Societe Generale
SHEL Shell
$48.00 /

-0.585 (-1.20%)

SHEL Shell
$48.00 /

-0.585 (-1.20%)

EQNR Equinor
$32.88 /

-0.64 (-1.91%)

SHEL Shell
$48.00 /

-0.585 (-1.20%)

EQNR Equinor
$32.88 /

-0.64 (-1.91%)

SHEL Shell
$48.00 /

-0.585 (-1.20%)

EQNR Equinor
$32.88 /

-0.64 (-1.91%)

Initiation
EyePoint initiated with a Buy at Chardan » 05:43
07/07/22
07/07
05:43
07/07/22
05:43
EYPT

EyePoint

$7.78 /

-0.02 (-0.26%)

Chardan analyst Daniil…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
EYPT EyePoint
$7.78 /

-0.02 (-0.26%)

EYPT EyePoint
$7.78 /

-0.02 (-0.26%)

11/16/21 Cantor Fitzgerald
EyePoint stock movement unwarranted, says Cantor Fitzgerald
11/15/21 Cowen
EyePoint price target raised to $35 from $25 at Cowen
11/15/21 Cowen
EyePoint price target raised to $35 from $25 at Cowen
11/15/21 Guggenheim
EyePoint price target raised to $75 from $22 at Guggenheim
EYPT EyePoint
$7.78 /

-0.02 (-0.26%)

  • 17
    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.